14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
IMMX vs NMTC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Immix Biopharma, Inc. (IMMX) captures the overall head-to-head institutional edge over NeuroOne Medical Technologies Corporation (NMTC) on higher Unified Composite conviction (50.6/100 HOLD vs. 45.5/100 HOLD) after splitting the core matrix 7–1 (led by Profitability & Quality), while NMTC wins 4–1 across the 6-pillar growth and valuation breakdown. IMMX trades at $6.96 (N/M Forward P/E, 0.0% operating margin) versus NMTC at $0.65 (N/M Forward P/E, -63.4% operating margin).
Growth vs. Quality Trade-Off: IMMX earns the overall head-to-head edge with a stronger Unified Composite Score (50.6/100 HOLD vs. NMTC 45.5/100 HOLD) and 1.65β · 76% Vol risk profile, whereas NMTC leads top-line expansion (+16.3% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: IMMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.7); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMMX vs NMTC. Trailing 12-month operating profitability (IMMX 0.0% vs NMTC -63.4%) and valuation multiples (IMMX N/M vs NMTC N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $6.1M market capitalization and -63.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ IMMX vs NMTC Key Questions & Quantitative Answers
As of Nov 20, 2026, Immix Biopharma, Inc. (IMMX) captures the overall head-to-head institutional edge over NeuroOne Medical Technologies Corporation (NMTC) on higher Unified Composite conviction (50.6/100 HOLD vs. 45.5/100 HOLD) after splitting the core matrix 7–1 (led by Profitability & Quality), while NMTC wins 4–1 across the 6-pillar growth and valuation breakdown. IMMX trades at $6.96 (N/M Forward P/E, 0.0% operating margin) versus NMTC at $0.65 (N/M Forward P/E, -63.4% operating margin). Growth vs. Quality Trade-Off: IMMX earns the overall head-to-head edge with a stronger Unified Composite Score (50.6/100 HOLD vs. NMTC 45.5/100 HOLD) and 1.65β · 76% Vol risk profile, whereas NMTC leads top-line expansion (+16.3% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: IMMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.7); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NMTC leads the Growth & Scale pillar: IMMX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NMTC at +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin). On trailing 12-month operating scale, IMMX generates N/A in USD-normalized revenue versus $12M for NMTC. In operating R&D and SG&A reinvestment, IMMX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NMTC.
NMTC screens cheaper on headline valuation multiples. IMMX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMMX (-27.0% ROE) versus NMTC (-124.7% ROE) capital efficiency.
In options market volatility and institutional positioning, IMMX carries 164.9% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.65β · 76% Vol realized risk). By comparison, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.